Fagron (ARSUF) Stock Price, News & Analysis

Company Overview

Fagron N.V. is a global pharmaceutical company focused on pharmaceutical compounding, the preparation of customized medicines for patients whose needs are not fully met by commercially available products. The company supplies pharmacies, hospitals, clinics and other healthcare professionals with products, services and expertise used to formulate individualized medications.

Its offerings include pharmaceutical raw materials, compounded medication products, formulation support, equipment and packaging, as well as technical and educational services. Fagron serves a range of therapeutic applications and supports both traditional compounding and specialized preparations, including medication forms tailored to patient-specific dosage, ingredient or administration requirements.

Founded in 1990 in Rotterdam, the Netherlands, Fagron has expanded through organic growth and acquisitions into a multinational organization. Its activities extend across Europe, North America, Latin America and other international markets, with regional operations and product portfolios adapted to local compounding practices and regulations. The company is headquartered in Rotterdam and is listed on the Euronext markets in Brussels and Amsterdam.

Key Stats

• Today's Range: $27.50 to $27.50
• 50-Day Range: $27.00 to $27.50
• 52-Week Range: $27.00 to $27.90
• Volume: N/A
• Average Volume: 112 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: 1.96%
• Price Target: N/A
• Consensus Rating: N/A

Fagron Stock Analysis - MarketRank™

Fagron scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Fagron.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Fagron is -19.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fagron is -19.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Fagron has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Fagron has recently increased by 52.34%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Fagron pays a meaningful dividend of 1.72%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Fagron does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

Fagron has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Fagron this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fagron insiders have not sold or bought any company stock.

Percentage Held by Institutions

53.76% of the stock of Fagron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ARSUF
• CIK: N/A
• Web: www.fagron.com
• Phone: 32.8.001.28.80
• Fax: N/A
• Employees: 3,282
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A